Evolution of the Average Target: Axsome Therapeutics, Inc.

Evolution of the Average Target - Axsome Therapeutics, Inc.

Evolution of the Target Price: Axsome Therapeutics, Inc.

Evolution of the Target Price - Axsome Therapeutics, Inc.

Changes in Analyst Recommendations: Axsome Therapeutics, Inc.

e39d5f1bb34b4bb1477cab15fbb97.HGlT4BGgOeGr8h6wgmWo0v7TRAD9_CGB9GgWBZ45Blc.WV840VzpVpHYlGzx1zLa4rm8DzOHjkXAuSwiddtbY3pMBWOhd-YM1ZirXw~73de531b8ea0b9f565a35368ab1165e2
04/11 Axsome Therapeutics Could Achieve Earnings in 2027 Amid Growing Auvelity Revenue, RBC Says MT
04/11 UBS Adjusts Axsome Therapeutics Price Target to $239 From $256, Maintains Buy Rating MT
04/11 Mizuho Trims Price Target on Axsome Therapeutics to $272 From $284, Keeps Outperform Rating MT
04/11 Deutsche Bank Trims Price Target on Axsome Therapeutics to $245 From $267, Keeps Buy Rating MT
03/11 RBC Lowers Price Target on Axsome Therapeutics to $273 From $295, Keeps Outperform Rating MT
15/10 Axsome Shows Valuation Disconnect Ahead of Q3, RBC Says MT
08/10 RBC Trims Price Target on Axsome Therapeutics to $295 From $297, Keeps Outperform Rating MT
29/09 Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating MT
26/09 Axsome's Auvelity Continues Positive Launch Trend, Mizuho Says MT
23/09 Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating MT
19/09 Axsome's Auvelity Launch Shows Early Strength in Alzheimer's Agitation, RBC Says MT
02/09 Axsome Therapeutics' Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation, RBC Says MT
12/08 UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating MT
12/08 Mizuho Adjusts PT on Axsome Therapeutics to $316 From $306, Keeps Outperform Rating MT
12/08 Axsome's Auvelity Strength Expected to Drive H2 Revenue Growth, RBC Says MT
11/08 Morgan Stanley Adjusts Axsome Therapeutics PT to $251 From $242, Keeps Equalweight Rating MT
11/08 RBC Adjusts PT on Axsome Therapeutics to $297 From $304, Maintains Outperform Rating MT
31/07 Mizuho Trims Price Target on Axsome Therapeutics to $306 From $310, Keeps Outperform Rating MT
21/07 BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target MT
07/07 RBC Capital Adjusts Axsome Therapeutics Price Target to $304 From $302, Maintains Outperform Rating MT
28/05 Axsome Sees Auvelity Momentum, Alzheimer's Agitation Approval Driving Growth Outlook, Oppenheimer Says MT
05/05 B. Riley Adjusts Price Target on Axsome Therapeutics to $300 From $230, Maintains Buy Rating MT
05/05 Mizuho Adjusts Price Target on Axsome Therapeutics to $310 From $228, Maintains Outperform Rating MT
05/05 RBC Raises Price Target on Axsome Therapeutics to $302 From $242, Keeps Outperform Rating MT
04/05 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+87.63%
+1.38%
-2.22%
+5.69%
-2.05%
+9.32%
-3.71%
+16.57%
-7.27%
+3.98%
Average +10.93%
Weighted average by Cap. +2.12%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
141.69USD
Average target price
265.86USD
Spread / Average Target
+87.63%
High Price Target
315.00USD
Spread / Highest target
+122.32%
Low Price Target
220.00USD
Spread / Lowest Target
+55.27%

Analyst Consensus Detail

Analyst consensus - Axsome Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Axsome Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Axsome Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. AXSM Stock
  4. Consensus Axsome Therapeutics, Inc.